Gelonghui May 10 丨 Yunnan Baiyao (000538)(000538gamesonblockchain.SZ) announced that Yunnan Baiyao Group Wuxi Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received a issuance from the State Drug Administration.gamesonblockchainThe Drug Clinical Trial Approval Notice (Notice No.: 2024LP00886), after review, it was agreed that flurbiprofen gel patch (hereinafter referred to as "the product") should be used for analgesia.gamesonblockchainclinical trials.
The main component of flurbiprofen gel patch is flurbiprofen, a non-steroidal anti-inflammatory drug that produces analgesic, anti-inflammatory and antipyretic effects by inhibiting the synthesis of prostaglandins. It is mainly suitable for the treatment of osteoarthritis, scapulohumeral periarthritis, tendon and tenosynovitis, peritenosynovitis, lateral humerus epicondylitis (tennis elbow), muscle pain, as well as swelling and pain caused by trauma and other diseases and symptoms. So far, approximately RMB 4.5 million has been invested in research and development expenses for this product.
